V-set and immunoglobulin domain containing 10 likeGenealiases: []
Q-omics provides the consensus-scored VSIG10L profile across patient tissues and cancer cell-line models. VSIG10L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VSIG10L is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, VSIG10L RNA expression shows 15,562 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where VSIG10L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VSIG10L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VSIG10L survival associations across molecular data types. VSIG10L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VSIG10L RNA expression–survival associations across cancer types. High VSIG10L expression shows unfavorable associations in KIRC, STAD, LIHC, LGG and KIRP, but favorable associations in UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VSIG10L RNA expression.
This table summarizes VSIG10L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for VSIG10L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VSIG10L shows lower tumor expression in HNSC and higher tumor expression in KIRP, LUAD, LIHC, LUSC and KIRC. The HNSC box plot shows higher VSIG10L RNA expression in normal versus tumor tissue (log2 FC = −2.617, t-test p < 0.001).
This table shows molecular features associated with VSIG10L in patient tissues and cancer cell lines. In patient samples, VSIG10L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, VSIG10L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
